To compare lesion anatomical responses to ranibizumab versus verteporfin photodynamic therapy (PDT) in the ANCHOR (Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization [CNV] in Age-Related Macular Degeneration) study.
B
ased on multiple lines of evidence that vascular endothelial growth factor A (VEGF-A), a diffusible cytokine that promotes angiogenesis and vascular permeability, plays a key role in the pathogenesis of neovascular age-related macular degeneration (AMD), [1] [2] [3] [4] Vascular endothelial growth factor A has been targeted in development of treatments for this disease. Ranibizumab (Lucentis; Genentech, Inc., South San Francisco, CA) is a recombinant humanized monoclonal antibody antigen-binding fragment (Fab) that binds to and neutralizes all known isoforms of human VEGF-A, as well as its active proteolytic cleavage products (including VEGF 110 ). 5, 6 The efficacy and safety of ranibizumab in treating neovascular AMD were established by 2 pivotal, Phase III, randomized, controlled, double-blind, multicenter trials: the ANCHOR (N = 423) study in patients with predominantly classic choroidal neovascularization (CNV) 7, 8 and the MARINA (N = 716) study in patients with minimally classic or occult without classic CNV. 9 In the ANCHOR (Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration) study, the primary efficacy analysis at 12 months showed that 94.3% of those treated with 0.3 mg ranibizumab and 96.4% of those treated with 0.5 mg ranibizumab lost ,15 letters from their baseline visual acuity score compared with 64.3% of those treated with verteporfin (Visudyne; Novartis Pharmaceuticals Corp., East Hanover, NJ) photodynamic therapy (PDT) (P , 0.0001 for each comparison vs. PDT). In addition, visual acuity improved by $15 letters at 12 months in 35.7% of the group receiving 0.3 mg of ranibizumab and 40.3% of the group receiving 0.5 mg of ranibizumab compared with 5.6% of the PDT group (P , 0.0001 for each comparison vs. PDT). Mean visual acuity increased by 8.5 letters in the group receiving 0.3 mg of ranibizumab and 11.3 letters in the group receiving 0.5 mg of ranibizumab compared with a decrease of 9.6 letters in the PDT group at 12 months (P , 0.0001 for each comparison vs. PDT). Similarly, the MARINA trial demonstrated clear superiority of 0.3 mg and 0.5 mg ranibizumab compared with sham control injections for visual acuity outcomes at 12 months (primary efficacy analysis). In both studies, the benefit of ranibizumab treatment was maintained at 24 months.
For the MARINA trial, lesion anatomical outcomes evaluated using fluorescein angiography (FA) in both treatment years and optical coherence tomography (OCT) in the first year were consistent with the visual acuity results in demonstrating superiority of ranibizumab over the sham control treatment in these patients with minimally classic or occult with no classic CNV. 10 We hypothesized that FA and OCT outcomes in the ANCHOR trial, which investigated ranibizumab in patients with a different angiographic subtype of CNV and compared ranibizumab with an active control treatment (PDT) rather than a sham-treated control, would similarly be consistent with the previously reported visual outcomes in ANCHOR in showing superiority of ranibizumab over the control treatment over time. We report here the results of this assessment of patients in the ANCHOR study, as evaluated by FA through 24 months and OCT through 12 months.
The FA outcomes of primary interest for this assessment included mean change from baseline in area of classic CNV and mean change from baseline in total area of leakage from CNV plus intense progressive retinal pigment epithelium staining (the central reading center's standard for evaluation of leakage from CNV, henceforth referred to as ''total area of CNV leakage''). Exploratory outcome measures based on FA at Months 12 and 24 included the proportion of patients with significant growth of CNV (defined as an increase of $0.3 disk diameters from baseline), mean changes from baseline in the total area of CNV lesion, total area of CNV, and area of serous sensory retinal detachment/ subretinal fluid (all prespecified measures), the percentage of patients with no leakage from CNV (i.e., total area of CNV leakage = 0), and mean change from baseline in area of subretinal fibrous tissue/disciform scar (post hoc measures). Exploratory measures of anatomical outcome based on OCT measures included mean change from baseline in center point thickness over time. Center point thickness was assessed at baseline (N = 53; 12 study centers), Day 7, Month 1, and Month 12 (N = 59; 13 study centers). Optical coherence tomography was not performed as part of the study during the second year.
Methods

Study Design
The design of the ANCHOR study has been described in detail elsewhere 7 and is briefly summarized here. In this Phase III, randomized, multicenter, double-masked trial, 423 patients aged 50 years and older were randomized 1:1:1 to receive monthly intravitreal injections of ranibizumab (0.3 or 0.5 mg) plus sham verteporfin (saline) PDT or monthly sham injections plus active verteporfin PDT for 24 months. Photodynamic therapy (with active or sham verteporfin) was administered at Study Day 0 and then quarterly as needed based on the investigator's evaluation of FA every 3 months. This study was funded by Genentech, Inc. and was sponsored by Genentech and Novartis Pharma AG. Genentech designed the study and was responsible for conduct of the study-including data collection, management, and analysis-and participated in manuscript preparation.
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Only one eye per patient was treated. The key eligibility criteria for the study eye were total lesion area greatest linear dimension #5,400 mm, bestcorrected visual acuity of 20/40 to 20/320 (Snellen equivalent) as assessed using Early Treatment Diabetic Retinopathy Study charts, no permanent structural damage (e.g., fibrosis or atrophy) to the central fovea, and no previous treatment (including verteporfin PDT) that might compromise assessment of the study treatment. A central reading center (University of Wisconsin Fundus Photograph Reading Center [UWFPRC]) assessed all FA and OCT images. The primary efficacy outcome was the proportion of patients with a loss of ,15 letters from baseline visual acuity at 12 months measured at a starting distance of 2 m.
Assessment of Anatomical Outcomes
Stereoscopic fundus photography, FA, and OCT were performed after formal certification of the study site's ophthalmic photographer by the UWFPRC to ensure standardization of image acquisition and quality. Fundus photography and FA were performed through a dilated pupil in all patients during the 28-day screening period preceding Study Day 0 and every 3 months through Month 24. Fluorescein angiography was used to assess changes from baseline in lesion characteristics in all patients. Definitions of lesion characteristics used by the UWFPRC are available in Supplemental Digital Content, http://links.lww.com/IAE/A22. The UWFPRC used trained masked graders to assess initial lesion eligibility about angiographic characteristics. These graders subsequently performed detailed CNV lesion grading and measurements using both fundus photographs and FA images from baseline and Months 6, 12, and 24. Graders used a comparative method in which the angiographic images from each subsequent study visit were compared with those from baseline.
The UWFPRC performed an interreader grading concordance exercise in August and September 2005. The UWFPRC regraded the baseline, Month 6, and Month 12 follow-up FA images from a pool of 13 patients from the MARINA trial and 12 patients from the ANCHOR trial. The total number of images graded was 74 (1 patient did not have all 3 visits). The intergrader concordance (as measured by intraclass correlation) was 0.82 for total lesion area, 0.87 for total CNV area, and 0.75 for the area of leakage.
Study centers for OCT assessment were selected based on the requirement that each center has OCT equipment (Stratus; Carl Zeiss, Dublin, CA) and availability of appropriately qualified personnel to use it. In the subset of OCT-assessed patients, 6-mm OCT macular scans were obtained. The 9 subfields, center point thickness, and total volume were measured using the automated Stratus algorithms at the clinical sites and included 6 retinal thickness analysis prints (1 print displaying each of the 6 individual radial line B-scans; each at a resolution of 128 A-scans/B-scan), 1 retinal map analysis print, and 2 crosshair prints (from the 512 A-scan/B-scanresolution crosshair scan displaying the vertical B-scan and the horizontal B-scan) centered through the fovea.
If the center point thickness measured using the computer software was identified as inaccurate (i.e., the standard deviation of the center point was .10%, 11 typically because of scan decentration or misidentification of the inner and/or outer retina boundaries), trained masked graders at the UWFPRC corrected it manually using calipers to measure the crosshair scan (averaging the values from the vertical and horizontal scans). The manual measurement was made from the internal limiting membrane to the presumed retinal pigment epithelium band on the OCT scan, and hence included any fluid or tissue in the subretinal space, but did not include any pigment epithelial detachment. In addition, OCT graders used the higher resolution crosshair scans to determine the presence of four distinct retinal morphologies: subretinal fluid, intraretinal cyst, pigment epithelial detachment, and CNV above or below the retinal pigment epithelial line. The height of the subretinal fluid at the center point was calculated using the manual measurement technique as described above, but thickness of the pigment epithelial detachment was not assessed. These additional data, however, are not readily available, and only manually measured retinal thickness data are presented-analogous to the MARINA study. 10 
Statistical Methods
Analyses were performed on an intent-to-treat basis (all randomized subjects), with the last-observation-carriedforward method used to impute missing data. For FA and fundus photography assessments, the mean changes from baseline to Months 12 and 24 in each of the ranibizumab groups were compared with those in the PDT group using the t-test from a stratified covariate-adjusted analysis of covariance model, with the baseline visual acuity score as the stratification variable (#44 and $45 letters) and the baseline value of the corresponding endpoint as a covariate. For significant growth of CNV (a categorical outcome), ranibizumab comparisons with PDT were based on the Cochran chi-square test, stratified by baseline visual acuity score. Percentages of patients with no leakage from CNV were compared using Pearson chi-square tests. Comparison of the pooled ranibizumab groups with the PDT group for change from baseline in center point thickness was performed using the t-test from an analysis of covariance model, with the baseline value of the corresponding endpoint as a covariate; absolute values of center point thickness at baseline and Month 12 were compared using Student's t-test. Statistical significance was assumed for P , 0.05. All analyses were prepared using SAS (version 9.1; SAS Institute, Cary, NC).
Results
Patient Retention and Treatment Exposure
Retention of patients throughout the 24-month study period was good in all groups but was better in the ranibizumab-treated groups: 110 of 143 patients (76.9%) in the PDT group completed the study compared with 117 of 140 patients (83.6%) in the group receiving 0.3 mg of ranibizumab and 116/140 patients (82.9%) in the group receiving 0.5 mg of ranibizumab. The mean (6SD) number of ocular injections (ranibizumab or sham) administered over 24 months in safety-evaluable patients (i.e., patients who received at least 1 study treatment) were 20.4 (66.1) in the PDT group (n = 143), 21.5 (65.0) in the group receiving 0.3 mg of ranibizumab (n = 137), and 21.3 (65.2) in the group receiving 0.5 mg of ranibizumab (n = 140). The mean (6SD) number of administrations of PDT (active or sham) over 24 months in safetyevaluable patients were 3.8 (62.0) in the PDT group (n = 143), 2.2 (61.9) in the group receiving 0.3 mg of ranibizumab (n = 137), and 1.9 (61.3) in the group receiving 0.5 mg of ranibizumab (n = 140). For the 50 patients randomized to PDT who crossed over in the second study year to receive monthly injections of 0.3 mg ranibizumab, the mean number of injections was 3.3 and the range was 1 to 6.
Patient Baseline Characteristics
Study eye baseline visual acuity scores and lesion anatomical characteristics were similar among the 3 treatment groups ( Table 1 ). The mean area of classic CNV ranged from 1.21 disk areas (DA) to 1.36 DA, and the mean total area of CNV leakage ranged from 2.92 DA to 3.06 DA. The mean total area of CNV lesion ranged from 1.79 DA to 1.89 DA, and the mean total area of CNV ranged from 1.31 DA to 1.48 DA.
Secondary Outcome Measures
The mean area of classic CNV increased from baseline in the PDT group but decreased from baseline in the †Total area of CNV leakage includes area of intense progressive staining of the retinal pigment epithelium, per standard definition used by the reading center.
‡For SSRD/subretinal fluid, the numbers of patients were 135 in the verteporfin PDT group, 124 in the group receiving 0.3 mg of ranibizumab, and 123 in the group receiving 0.5 mg of ranibizumab.
§For subretinal fibrous tissue/fibrin or disciform scar, the numbers of patients were 138 in the verteporfin PDT group, 134 in the group receiving 0.3 mg of ranibizumab, and 135 in the group receiving 0.5 mg of ranibizumab.
CNV, choroidal neovascularization; DA, disk areas; PDT, photodynamic therapy; SD, standard deviation; SSRD, serous sensory retinal detachment. ranibizumab groups at Months 12 and 24 (P , 0.0001 for each comparison vs. PDT) (Table 2; Figure 1A ). Whereas the PDT group had a mean increase from baseline at Month 12 and a mean decrease from baseline at Month 24 in total area of CNV leakage, the 2 ranibizumab-treated groups had mean decreases at Months 12 and 24 (P , 0.0001 for each comparison vs. PDT) (Table 2; Figure 1B ).
Fluorescein Angiography Exploratory Outcome Measures
Study eyes treated with ranibizumab, on average, exhibited slight growth in the total area of the CNV lesion from baseline to Month 12 (increase of 0.38 from 1.89 DA in the 0.3-mg group, and increase of 0.28 from 1.79 DA in the 0.5-mg group) and from Month 12 to Month 24 (additional increases of 0.14 and 0.11 DA for the 0.3-mg and 0.5-mg groups, respectively). In contrast, mean lesion area in the PDT group had grown substantially by Month 12 and was an average of 2.89 DA larger than the 1.88 DA baseline by Month 24 (P , 0.0001 for each ranibizumab dose group vs PDT at Month 12 and Month 24) (Table 2, Figure 1 , Panel C). Significant growth of CNV at Month 24 (i.e., an increase from baseline of $0.3 disk diameters) was observed in 81 of 143 patients (56.6%) in the PDT group, 33 of 140 patients (23.6%) in the group receiving 0.3 mg of ranibizumab, and 43 of 140 patients (30.7%) in the group receiving 0.5 mg of ranibizumab (P , 0.0001 for each dose group vs. PDT); these percentages were similar to those at Month 12.
At Months 12 and 24, the mean area of serous sensory retinal detachment/subretinal fluid had decreased from baseline significantly more in the 2 ranibizumab groups compared with the PDT group (P , 0.001 for each comparison vs. PDT) ( Table 2 ; Figure 1D ).
At Month 12, 10 of 143 patients (7.0%) in the PDT group, 48 of 140 patients (34.3%) in the group receiving 0.3 mg of ranibizumab, and 60 of 140 patients (42.9%) in the group receiving 0.5 mg of ranibizumab exhibited no leakage from CNV The last-observation-carried-forward method was used to impute missing data. Strata were defined using the baseline visual acuity score (#44 vs. $45 letters).
*Derived from the t distribution. †Total area of CNV leakage includes area of intense progressive staining of the retinal pigment epithelium, per standard definition used by the reading center.
§For subretinal fibrous tissue/disciform scar, the numbers of patients were 138 in the verteporfin PDT group, 134 in the group receiving 0.3 mg of ranibizumab, and 135 in the group receiving 0.5 mg of ranibizumab.
CNV, choroidal neovascularization; DA, disk areas; PDT, photodynamic therapy; CI, confidence interval; SD, standard deviation; SSRD, serous sensory retinal detachment.
(P , 0.0001 for each comparison vs. PDT). At Month 24, these numbers had increased to 50 of 143 patients (35.0%) in the PDT group, 87 of 140 patients (62.1%) in the group receiving 0.3 mg of ranibizumab, and 85 of 140 patients (60.7%) in the group receiving 0.5 mg of ranibizumab (P , 0.0001 for each comparison vs. PDT) (Figure 1E ).
At Months 12 and 24, the area of subretinal fibrous tissue/disciform scar increased slightly more from baseline in the PDT group than the ranibizumab groups, although this was only statistically significant between the group receiving 0.3 mg of ranibizumab and the PDT group at Month 24 (P = 0.0007 vs. PDT) (Table 2; Figure 1F ).
Optical Coherence Tomography Exploratory Outcome Measure
Optical coherence tomography data (obtained during the first year only and available for a subset Fig. 1 . A. Mean change from baseline in area of classic CNVover time. P , 0.0001 versus PDT for each ranibizumab dose at each time point. B. Mean change from baseline in total area of CNV leakage over time. P , 0.0001 versus PDT for each ranibizumab dose at each time point. C. Mean change from baseline in total area of CNV lesion over time. P , 0.0001 versus PDT for each ranibizumab dose at each time point. D. Mean change from baseline in area of SSRD/subretinal fluid. P , 0.0001 versus PDT for each ranibizumab dose at each time point, except P = 0.0004 for 0.3-mg dose at Month 24. E. Percentage of patients with no CNV leakage. For 0.3-mg ranibizumab dose, P = 0.029 and P = 0.0005 versus PDT at Months 3 and 6, respectively, and P , 0.0001 versus PDT at all other time points. For 0.5-mg ranibizumab dose, the difference from PDT was not statistically significant at Month 3, but P , 0.0001 versus PDT at all other time points. F. Mean change from baseline in area of subretinal fibrous tissue/disciform scar. Differences between the PDT group and the ranibizumab groups were not statistically significant at Months 3 through 12. For 0.3-mg ranibizumab dose, P = 0.040 versus PDT at Month 15, P = 0.0026 at Month 18, and P = 0.0007 at Months 21 and 24. For 0.5-mg ranibizumab dose, P = 0.027 versus PDT at Month 15, P = 0.0054 at Month 18, and P = 0.0030 at Month 18; the difference at Month 24 was not statistically significant. CNV leakage, CNV leakage plus intense progressive staining of retinal pigment epithelium; SSRD, serous sensory retinal detachment. Vertical bars = 61 standard error of the mean; 61 asymptotic standard error for percentage of patients with no CNV leakage. of patients) were assessed to determine the center point thickness (Figure 2, A and B) . Center point thickness evaluated as mean change from baseline was decreased at 12 months in the PDT and pooled ranibizumab treatment groups; however, there was a significantly greater decrease in ranibizumab-treated patients (P = 0.0003, pooled ranibizumab groups vs. PDT group). A significantly greater reduction in center point thickness could be observed within 7 days of the initial treatment in ranibizumab-treated patients compared with PDT patients (P = 0.0095, pooled ranibizumab groups vs. PDT group), and this was maintained through Month 12. Changes in total retinal volume and central retinal thickness were also measured by OCT, and the findings for PDT and ranibizumab-treated patients were consistent with those for center point thickness (data not shown). Figure 3 shows the fundus photographs and FA images for the study eye at baseline and Months 12 and 24 of an 83-year-old patient in the ANCHOR study. The patient's OCT images and center point thickness measurements at baseline, study Day 7, and Month 12 are also shown. The patient had received no previous treatments for neovascular AMD and was randomized to the group receiving 0.5 mg ranibizumab. The study eye's baseline characteristics included a total lesion area of 2.00 DA, center point thickness of 320 mm, and visual acuity of 20/80 22 (53 Early Treatment Diabetic Retinopathy Study letters). Fluorescein angiography at baseline confirmed that the lesion type was predominantly classic and that it involved the fovea. Seven days after the first injection of ranibizumab, the center point thickness was reduced (with resolution of the foveal cyst) and visual acuity improved by 11 letters to 20/50
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. During 12 months of treatment with ranibizumab, the predominantly classic lesion stabilized, center point thickness was reduced, and the patient's visual acuity remained stable. Comparison of baseline and Month 12 OCT images revealed improvements in foveal architecture resulting from ranibizumab treatment, including reduction in cystic changes within the fovea and a return to a more normal foveal thickness. At Month 24, the patient's visual acuity continued to be stable and lesion stability was apparent by funduscopic examination that was confirmed by FA showing no evidence of CNV leakage.
Discussion
In the ANCHOR study, patients with predominantly classic CNV secondary to neovascular AMD who were treated with intravitreal ranibizumab demonstrated early and sustained improvement that was consistent for visual acuity, 7 FA, and OCT outcomes and superior to that in the PDT control group. Generally, the CNV lesion in ranibizumab-treated patients did not recede or disappear but did demonstrate less fibrosis and less exudation compared with PDT-treated lesions, as measured by most anatomical outcomes (e.g., decrease in the area of leakage from CNV, subretinal fluid area, predominantly classic CNV lesion size, and center point retinal thickness on OCT). In addition, the size of the CNV lesion was stabilized over time with ranibizumab treatment-and to a greater extent when compared with PDT, where the total CNV lesion size increased. For PDT patients who crossed over to ranibizumab injections during the second study year, ranibizumab treatment would be expected, on average, to restrain lesion size growth, thereby reducing the change from baseline during that time compared with what might have occurred in the absence of treatment. Because the groups randomized to ranibizumab treatment showed significantly less lesion size growth at all time points compared with that randomized to PDT, the PDT patient crossover should not affect this interpretation. Similar to the functional outcomes (bestcorrected visual acuity), there was no attrition of the early anatomical benefits and the effect persisted through the final (second) year of the study, based primarily on FA parameters.
Results similar to those reported here were observed for anatomical outcomes in the MARINA study of patients with minimally classic or occult without classic CNV lesions. 10 It is encouraging to see consistency in ranibizumab treatment benefit not only between anatomical and functional outcomes within each study (MARINA and ANCHOR) but also across trials. The MARINA study anatomical outcomes parallel closely those seen in the ANCHOR study. In both ANCHOR and MARINA, total area of CNV leakage was significantly reduced by the third month in the ranibizumab groups, continued to decrease through Month 12, and was relatively stable during the second year of treatment. While most anatomical parameters showed similar trends in ANCHOR and MARINA over 2 years of follow-up, the total area of CNV lesion and the total area of CNV leakage appear consistently to show the biggest numeric differences between the ranibizumab treatment and the control treatment. This may reflect the strong antipermeability effect of VEGF inhibition on the CNV process in both predominantly classic and minimally classic or occult without classic lesions. The similarity of anatomical outcomes between MARINA and ANCHOR indicates a consistency of treatment effect with ranibizumab despite the different underlying CNV phenotypes.
The proportion of patients whose lesions showed no leakage from CNV was substantially greater in the ranibizumab groups than in the PDT group by Month 6 and remained so at Months 12 and 24; in all groups, these proportions increased markedly over time, but by Month 24, nearly two thirds of ranibizumab-treated patients had dry lesions compared with approximately one third in the PDT group. Although it is difficult to compare across trials, the proportions in the ranibizumab groups with no leakage from CNV were also higher at 12 and 24 months than was previously reported for PDT patients with predominantly classic CNV in the TAP studies (14 and 45%, respectively). 12 It should be noted that the proportions of patients treated with PDT in ANCHOR who had dry lesions at these time points were lower than those in TAP, possibly due in part to a difference in the definition of leakage from CNV used by the independent FA image readers for the two trials. For example, for the ANCHOR trial, the reading center's standard for assessment of the total area of CNV leakage included the intense progressive staining of the retinal pigment epithelium plus the total area of CNV leakage. This may have resulted in a higher sensitivity (and possibly lower specificity) for the detection of leakage in the ANCHOR trial compared with other studies, such as TAP.
It is also interesting that although the percentage of patients in the PDT group with no leakage from CNV rose 5-fold (from 7 to 35%) between Months 12 and 24, while the percentage in the ranibizumab groups increased by only approximately 50% during this interval, this difference was not reflected in any appreciable diminution in the visual acuity difference between the PDT and the ranibizumab groups at Month 24. In the ranibizumab groups, the 50% increase in the percentage of patients with dry lesions between Months 12 and 24 can probably be attributed to an interplay of factors, including continued incremental response to ranibizumab. Although OCT was conducted in only a subset of patients and only through Month 12, the findings for center point thickness are consistent with those for FA in the overall PDT and ranibizumab groups. The reductions from baseline in center point thickness in ranibizumab-treated patients at Month 12 represented a change, on average, from 403 mm to 210 mm, thus representing a normalization of thickness rather than an atrophic thinning process ( Figure 2B ). The mean reduction achieved was approximately twice that achieved in the PDT group. Measurements of retinal volume and retinal thickness were consistent with the findings for center point thickness.
The lesion anatomical findings reported here for ANCHOR and previously for the MARINA study demonstrate the ability of ranibizumab to substantively arrest the pathologic process in neovascular AMD, allowing a normalization of macular anatomy as well as providing a clinically significant improvement in visual acuity in many patients. In the interval since the start of these two pivotal trials of ranibizumab, OCT has become a more widely available technology in ophthalmic practices and promises to provide an important tool, along with FA, in determining the optimal application of ranibizumab therapy for individual patients. The results achieved with monthly ranibizumab treatment in patients with all types of CNV lesions in the 2-year MARINA and ANCHOR studies have significantly changed the treatment paradigm for neovascular AMD. Lesion changes and visual acuity improvements achievable with alternative ranibizumab dosing schedules and over longer treatment durations are under investigation.
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